Research programme: peptide-based therapeutics - Phylogica/Johnson & Johnson Research

Drug Profile

Research programme: peptide-based therapeutics - Phylogica/Johnson & Johnson Research

Latest Information Update: 21 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson; Phylogica
  • Class Peptide fragments
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 21 Apr 2010 Preclinica development is ongoing in Australia
  • 12 Jul 2006 Preclinical trials in Undefined in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top